SCHEMBL31332903

SCHEMBL31332903

CCn1cnc(S(C)(=O)=O)c1C(=O)OC

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 1/20 0.35
BRD4 O60885 1/20 0.35
ALDH1A1 P00352 6/20 0.33
KDM4E B2RXH2 5/20 0.33
HPGD P15428 3/20 0.33
GAA P10253 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
GLA P06280 1/20 0.33
HTT P42858 1/20 0.33
HSD17B10 Q99714 1/20 0.33
NOTUM Q6P988 1/20 0.33
GLP1R P43220 1/20 0.33
LPO P22079 2/20 0.33
LMNA P02545 1/20 0.32
MAPK8 P45983 1/20 0.32
HTR7 P34969 1/20 0.32
HTR6 P50406 1/20 0.32
IDO1 P14902 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12724434 0.78 ALDH1A1 (0.41) NR4A2BRD4ALDH1A1GAAHTT
SCHEMBL31333053 0.76 NR4A2 (0.38) NR4A2BRD4ALDH1A1KDM4ENOTUM
SCHEMBL31332845 0.76 NR4A2 (0.38) NR4A2BRD4ALDH1A1KDM4EHPGD
SCHEMBL31333016 0.76 NR4A2 (0.38) NR4A2BRD4ALDH1A1KDM4EHPGD
SCHEMBL31332867 0.74 ALDH1A1 (0.38) NR4A2BRD4ALDH1A1KDM4ENOTUM
SCHEMBL31333021 0.73 CYP11B1 (0.41) NR4A2BRD4ALDH1A1KDM4EHPGD
SCHEMBL31332892 0.73 NR4A2 (0.35) NR4A2BRD4ALDH1A1KDM4EHPGD
SCHEMBL31333004 0.73 NR4A2 (0.35) NR4A2BRD4ALDH1A1KDM4ENOTUM
SCHEMBL31332848 0.72 RAD52 (0.38) NR4A2BRD4ALDH1A1KDM4EHPGD
SCHEMBL28016210 0.72 SMN1; SMN2 (0.42) ALDH1A1KDM4EGAASMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709374-A2 KCC2 POTENTIATORS AND USES THEREOF Axonis Therapeutics, Inc. (US) 2026-03-18 EP disclosed
US-20260062402-A1 KCC2 POTENTIATORS AND USES THEREOF AXONIS THERAPEUTICS INC (US) 2026-03-05 US disclosed
WO-2024233885-A2 KCC2 POTENTIATORS AND USES THEREOF AXONIS THERAPEUTICS, INC. (US) 2024-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062402-A1 KCC2 POTENTIATORS AND USES THEREOF HCN2, HCN1, HCN4 NR4A2 1321/4885BRD4 3398/4885ALDH1A1 2748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.